Quanterix Corporation (QTRX)
| Market Cap | 258.31M |
| Revenue (ttm) | 138.90M |
| Net Income (ttm) | -107.15M |
| Shares Out | 46.71M |
| EPS (ttm) | -2.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 428,538 |
| Open | 6.02 |
| Previous Close | 6.33 |
| Day's Range | 5.34 - 6.50 |
| 52-Week Range | 4.05 - 8.77 |
| Beta | 1.12 |
| Analysts | Hold |
| Price Target | 11.33 (+104.88%) |
| Earnings Date | Mar 2, 2026 |
About QTRX
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of ... [Read more]
Financial Performance
In 2025, Quanterix's revenue was $138.90 million, an increase of 1.07% compared to the previous year's $137.42 million. Losses were -$107.15 million, 178.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for QTRX stock is "Hold." The 12-month stock price target is $11.33, which is an increase of 104.88% from the latest price.
News
Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript
Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the f...
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on...
Quanterix to Participate in Upcoming Investor Conferences
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has...
Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced public...
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diag...
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diag...
Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced public...
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diag...
Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the pu...
Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript
Quanterix Corporation ( QTRX) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Joshua Young Masoud Toloue - President, CEO & Director Vandana Sriram - CFO & Treasurer Conferen...
Quanterix Releases Financial Results for the Third Quarter of 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financ...
Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen...
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Departmen...
Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its executive leadershi...
Quanterix Corporation (QTRX) Q2 2025 Earnings Call Transcript
Quanterix Corporation (NASDAQ:QTRX) Q2 2025 Earnings Conference Call August 7, 2025 4:30 AM ET Company Participants Joshua Young - Corporate Participant Masoud Toloue - President, CEO & Director Vand...
Quanterix Releases Financial Results for the Second Quarter of 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the s...
Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen...
Quanterix Announces Cooperation Agreement with Kent Lake Capital
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announc...
Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commerc...
Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announ...
Quanterix Expands Reach with IVD and Large Reference Labs
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoas...
Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders
RINCON, Puerto Rico , June 11, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company...